Jul 8, 2018

Hidden conflicts? Pharma payments to FDA advisers after drug approvals spark ethical concerns

Posted by in categories: finance, futurism

Brilinta fits a pattern of what might be called pay-later conflicts of interest, which have gone largely unnoticed—and entirely unpoliced. In examining compensation records from drug companies to physicians who advised FDA on whether to approve 28 psychopharmacologic, arthritis, and cardiac or renal drugs between 2008 and 2014, Science found widespread after-the-fact payments or research support to panel members. The agency’s safeguards against potential conflicts of interest are not designed to prevent such future financial ties.

Science investigation of journal disclosures and pharmaceutical funding records shows potential influence on physician gatekeepers.

Read more

Comments are closed.